Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing advanced healthcare solutions and addressing the needs of patients suffering from chronic pain and inflammation.

Etoricoxib, the active ingredient in Relixib, belongs to a class of medications known as selective COX-2 inhibitors, offering targeted relief from pain and swelling associated with various arthritic conditions, including osteoarthritis, rheumatoid arthritis, and gout. The 120mg dosage has been carefully selected to optimize efficacy while minimizing potential side effects, ensuring a better quality of life for patients.

“Through the launch of Relixib, Crassula Honduras underscores its ongoing commitment to enhance healthcare outcomes with innovative and accessible treatment options. Relixib exemplifies our mission to address unmet medical needs in the management of pain and inflammation,” stated Dr. Bhawana Gupta, CTO of Crassula Pharmaceuticals. “We are proud to offer this significant advancement in pain management to the people of Honduras, furthering our goal of making superior healthcare solutions readily accessible.”

Relixib is now available in Honduras, offering a new hope for patients seeking effective management of chronic pain and inflammatory conditions. For more information about Relixib and other Crassula Pharmaceuticals products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Honduras

Crassula Honduras is a division of Crassula Pharmaceuticals, a company synonymous with high-quality healthcare products. With a focus on innovation, quality, and patient safety, Crassula strives to improve health and well-being in Honduras and beyond. The company’s diverse product portfolio meets a wide range of healthcare needs, ensuring that patients have access to the latest advancements in medical treatment.